nach oben

The European Journal of Health Economics

Erschienen in:

01.02.2010 | Original Paper

Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis

verfasst von: Yogesh Suresh Punekar, Neil Hawkins

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Infliximab has been shown to be efficacious in acute exacerbations of ulcerative colitis (UC).

Aim

To evaluate the cost-effectiveness of infliximab treatment in patients hospitalised with acute exacerbations of UC.

Methods

A decision analysis model was constructed to simulate the progression of acute UC patients treated with infliximab induction regimen over 1 year. Infliximab treatment was compared with standard care, ciclosporin and surgery using transitions derived from infliximab and ciclosporin randomised trials. Costs and outcomes were discounted at 3.5%. Intermediate outcomes of colectomy and post-surgery complications were translated into the primary effectiveness measurement, which was quality-adjusted life years (QALYs) estimated using EQ-5D. One-way and probabilistic sensitivity analyses were performed to estimate the uncertainty around the results.

Results

The incremental cost effectiveness ratio (ICER) for infliximab was £19,545 per QALY compared to ciclosporin, which in turn dominated standard care. Sensitivity analysis indicated patient body weight, utility estimates and treatment effect of alternative treatment strategies to be the most important factors affecting cost-effectiveness.

Conclusion

Infliximab induction regimen appears to be a cost-effective treatment option for UC patients hospitalised with an acute exacerbation.

Carter, M.J., Lobo, A.J., Travis, S.P.: Guidelines for the management of inflammatory bowel disease in adults. Gut 53(5), V1–V16 (2004)CrossRef

Jarnerot, G., Rolny, P., Sandberg-Gertzen, H.: Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89(5), 1005–1013 (1985)

Truelove, S.C., Jewell, D.P.: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1(7866), 1067–1070 (1974)CrossRef

Leiper, K., Lowe, D., Driscoll, R., et al.: UK IBD audit 2006: National results for the organisation and process of IBD care in the UK. Published 2007; available at http://www.rcplondon.ac.uk/college/ceeu/ceeu_uk_ibd_audit_2006.pdf

Travis, S., Trange, E., Lemann, A., et al.: European evidence based consensus on the diagnosis and management of ulcerative colitis: current management. J. Crohn’s Colitis 2, 24–62 (2008)CrossRef

Arts, J., D’Haens, G., Zeegers, M., et al.: Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflam. Bowel Dis. 10, 73–78 (2004)CrossRef

Sandborn, W.J.: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam. Bowel Dis. 1, 48–63 (1995)CrossRef

Jarnerot, G., Hertervig, E., Friis-liby, I., et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized placebo controlled study. Gastroenterology 128, 1805–1811 (2005)CrossRef

Sands, B.E., Tremaine, W.J., Sandborn, W.J., Rutgeerts, P.J., Hanauer, S.B., Mayer, L., Targan, S.R., Podolsky, D.K.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflam. Bowel Dis. 7(2), 83–88 (2001)CrossRef

10.

Tsai, H.H., Punekar, Y.S., Morris, J., et al.: A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment. Pharmacol. Ther. 15;28(10), 1230–1239 (2008)CrossRef

11.

D’Haens, G., Lemmens, L., Geboes, K., et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120(6), 1323–1329 (2001)CrossRef

12.

Lichtiger, S., Present, D.H., Kornbluth, A., et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330(26), 1841–1845 (1994)CrossRef

13.

Ades, A., Welton, N., Caldwell, D., et al.: Multiparameter evidence synthesis in epidemiology and medical decision-making. J. Health Serv. Res. Policy 13(Suppl 3), 12–22 (2008)CrossRef

14.

Lunn, D.J., Thomas, A., Best, N., Spiegelhalter, D.: WinBUGS–a Bayesian modelling framework: concepts, structure, and extensibility. Stat. Comput. 10, 325–337 (2000)CrossRef

15.

Reference costs 2006/07: National schedule of reference costs. Department of Health. January 2008

16.

Woehl, A., Hawthorne, B., Morgan, C., Punekar, Y., McEwan, P.: The epidemiology and healthcare resource use in patients with Crohn’s disease: a population based UK study. Value Health 10(6), A355 (2007)

17.

Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35(11), 1095–1108 (1997)CrossRef

18.

Walmsley, R.S., Ayres, R.C.S., Pounder, R.E., Allan, R.N.: A simple clinical colitis activity index. Gut 43(10), 29–32 (1998)CrossRef

19.

Arseneau, K., Sultan, S., Provenzale, D., et al.: Do patient preferences influence decisions on treatment for patients with steroid refractory ulcerative colitis? Clin. Gastroenterol. Hepatol. 4(9), 1135–1142 (2006)CrossRef

20.

National Institute of Health and Clinical Excellence (NICE): Guide to the Methods of Technology Appraisal (reference NO515). NICE, London, (2004), http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf

21.

Kohn, A., Daperno, M., Armuzzi, A., et al.: Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther. 26(5), 747–756 (2007)CrossRef

22.

National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Psoriasis. London: Technology Appraisal Guidance 134, January (2008), http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Guidelines/NICE-guidance-on-the-use-of-infliximab-for-the-treatment-of-psoriasis/

23.

Laharie, D.: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF). Clinicaltrials.gov identifier–NCT00542152, http://clinicaltrials.gov/ct2/show/NCT00542152

Titel: Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis
verfasst von: Yogesh Suresh Punekar
Neil Hawkins
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 1/2010
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-009-0199-5

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach

An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?

Cost effectiveness of palivizumab in Spain: an analysis using observational data

Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected

Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study